Your browser doesn't support javascript.
Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19.
Kuo, Tsun-Yung; Lin, Meei-Yun; Coffman, Robert L; Campbell, John D; Traquina, Paula; Lin, Yi-Jiun; Liu, Luke Tzu-Chi; Cheng, Jinyi; Wu, Yu-Chi; Wu, Chung-Chin; Tang, Wei-Hsuan; Huang, Chung-Guei; Tsao, Kuo-Chien; Chen, Charles.
  • Kuo TY; Medigen Vaccine Biologics Corporation, Taipei, Taiwan.
  • Lin MY; Department of Biotechnology and Animal Science, National Ilan University, Yilan City, Yilan County, Taiwan.
  • Coffman RL; Medigen Vaccine Biologics Corporation, Taipei, Taiwan.
  • Campbell JD; Dynavax Technologies, Emeryville, CA, 94608, USA.
  • Traquina P; Dynavax Technologies, Emeryville, CA, 94608, USA.
  • Lin YJ; Dynavax Technologies, Emeryville, CA, 94608, USA.
  • Liu LT; Medigen Vaccine Biologics Corporation, Taipei, Taiwan.
  • Cheng J; Medigen Vaccine Biologics Corporation, Taipei, Taiwan.
  • Wu YC; Medigen Vaccine Biologics Corporation, Taipei, Taiwan.
  • Wu CC; Medigen Vaccine Biologics Corporation, Taipei, Taiwan.
  • Tang WH; Medigen Vaccine Biologics Corporation, Taipei, Taiwan.
  • Huang CG; Medigen Vaccine Biologics Corporation, Taipei, Taiwan.
  • Tsao KC; Department of Laboratory Medicine, Linkou Chang Gung Memorial Hospital, Taoyuan City, Taiwan.
  • Chen C; Research Center for Emerging Viral Infections, College of Medicine, Chang Gung University, Taoyuan City, Taiwan.
Sci Rep ; 10(1): 20085, 2020 11 18.
Article in English | MEDLINE | ID: covidwho-933722
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
The COVID-19 pandemic is a worldwide health emergency which calls for an unprecedented race for vaccines and treatment. In developing a COVID-19 vaccine, we applied technology previously used for MERS-CoV to produce a prefusion-stabilized SARS-CoV-2 spike protein, S-2P. To enhance immunogenicity and mitigate the potential vaccine-induced immunopathology, CpG 1018, a Th1-biasing synthetic toll-like receptor 9 (TLR9) agonist was selected as an adjuvant candidate. S-2P in combination with CpG 1018 and aluminum hydroxide (alum) was found to be the most potent immunogen and induced high titer of neutralizing antibodies in sera of immunized mice against pseudotyped lentivirus reporter or live wild-type SARS-CoV-2. In addition, the antibodies elicited were able to cross-neutralize pseudovirus containing the spike protein of the D614G variant, indicating the potential for broad spectrum protection. A marked Th1 dominant response was noted from cytokines secreted by splenocytes of mice immunized with CpG 1018 and alum. No vaccine-related serious adverse effects were found in the dose-ranging study in rats administered single- or two-dose regimens of S-2P combined with CpG 1018 alone or CpG 1018 with alum. These data support continued development of CHO-derived S-2P formulated with CpG 1018 and alum as a candidate vaccine to prevent COVID-19 disease.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Spike Glycoprotein, Coronavirus / Immunogenicity, Vaccine / COVID-19 Vaccines Type of study: Randomized controlled trials Topics: Vaccines / Variants Limits: Animals / Female / Humans Language: English Journal: Sci Rep Year: 2020 Document Type: Article Affiliation country: S41598-020-77077-z

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Spike Glycoprotein, Coronavirus / Immunogenicity, Vaccine / COVID-19 Vaccines Type of study: Randomized controlled trials Topics: Vaccines / Variants Limits: Animals / Female / Humans Language: English Journal: Sci Rep Year: 2020 Document Type: Article Affiliation country: S41598-020-77077-z